Skip to main content

Research Repository

See what's under the surface

Analogue peptides for the immunotherapy of human acute myeloid leukemia

Hofmann, Susanne; Mead, Andrew; Malinovskis, Aleksandrs; Hardwick, Nicola R.; Guinn, Barbara-ann


Susanne Hofmann

Andrew Mead

Aleksandrs Malinovskis

Nicola R. Hardwick


The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials. However, responses are often short-lived and rarely induce notable memory responses. The reason is that self-antigens have already been presented to the immune system as the tumor develops, leading to tolerance or some degree of host tumor cell destruction. To try to break tolerance against self-antigens, one of the methods employed has been to modify peptides at the anchor residues to enhance their ability to bind major histocompatibility complex molecules, extending their exposure to the T-cell receptor. These modified or analogue peptides have been investigated as stimulators of the immune system in patients with different cancers with variable but sometimes notable success. In this review we describe the background and recent developments in the use of analogue peptides for the immunotherapy of acute myeloid leukemia describing knowledge useful for the application of analogue peptide treatments for other malignancies.

Journal Article Type Article
Publication Date 2015-11
Journal Cancer Immunology, Immunotherapy
Print ISSN 0340-7004
Electronic ISSN 1432-0851
Publisher Springer Verlag
Peer Reviewed Peer Reviewed
Volume 64
Issue 11
Pages 1357-1367
Institution Citation Hofmann, S., Mead, A., Malinovskis, A., Hardwick, N. R., & Guinn, B. (2015). Analogue peptides for the immunotherapy of human acute myeloid leukemia. Cancer Immunology, Immunotherapy, 64(11), 1357-1367.
Keywords Analogue peptides; Adult acute myeloid leukemia; Clinical trials; PASD1; Heteroclitic peptides; NPM1
Publisher URL